TABLE 5

In vitro activity of imipenem-relebactam against the most common MDR phenotypes of P. aeruginosaa

Phenotypean (% of all MDR)Imipenem-relebactam
MIC90 (μg/ml)% susceptible
All P. aeruginosa896294.4
    All MDR264b482.2
        ATM, CAZ, CIP, FEP, IMI, P/T57 (21.6)864.9
        ATM, CAZ, FEP, P/T53 (20.1)0.5100
        ATM, CAZ, FEP, IMI, P/T24 (9.1)487.5
        AMK, ATM, CAZ, CIP, FEP, IMI, P/T13 (4.9)3253.8
        ATM, CIP, FEP, IMI, P/T12 (4.5)858.3
        ATM, CAZ, P/T12 (4.5)0.5100
        ATM, CAZ, CIP, FEP, P/T10 (3.8)0.5100
  • a Sentinel agents used for the definition of MDR included amikacin (AMK), aztreonam (ATM), cefepime (FEP), ceftazidime (CAZ), ciprofloxacin (CIP), colistin, imipenem (IMI), and piperacillin-tazobactam (P/T). The MDR phenotypes listed accounted for 68.7% (181/264) of all MDR phenotypes identified; colistin resistance was not observed among the most common MDR phenotypes identified. Agents shown in the table tested as nonsusceptible; the other sentinel agents tested as susceptible. Agents tested but not included in the list of sentinel agents may have tested as susceptible or nonsusceptible.

  • b MDR isolates accounted for 29.5% (264/896) of all isolates of P. aeruginosa.